TMRW
7.12.2021 15:50:06 CET | Business Wire | Press release
Tmrw, a new and scalable Learning Operating System (LearnOS) for global education with a mission to help bring a quality education to every child, was launched this month.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005768/en/
Its interoperable All-In-One Integrated Platform is built to be accessible and affordable for Government funded schools operating in both the developed and developing world settings. In particular, it seeks to reach all students irrespective of their background or their ability to pay. It is designed to cater to the needs of every curriculum, context and mode of learning, whether brick and mortar, virtual or blended. Tmrw’s vision over time is to underpin learning, teaching, and the operational needs of K12 education, higher education and life-long learning.
Sunny Varkey, who also founded the Global Teacher Prize, has ensured that Tmrw has been teacher-led from the drawing board to its final roll-out. Uniquely, he has been able to draw upon the teaching talent within the GEMS schools network, which includes 20,000 inspired and qualified teachers, teaching support staff and school administrators from all nationalities, delivering seven different curricula in 16 countries.
The ongoing COVID-19 pandemic has emphasised the urgent need for an integrated technological solution for global education that can streamline end-to-end processes and utilise data to improve teaching and learning, while providing a seamless experience for all. Tmrw seeks to fill this void by providing an education eco-system that offers far more than a traditional, stand-alone learning or school management system. Working in collaboration with schools and teachers, our ambition is that Tmrw becomes an accepted LearnOS of global education – giving every learner an opportunity to participate in the future.
Tmrw’s EdTech platform includes a comprehensive suite of modules that can be introduced as a full ecosystem or as bolt-ons that are interoperable with technologies from other providers, offering schools the efficiency gains that integration can bring.
The platform includes modules to manage and oversee the curriculum, assessment, and track student progress. It has non-academic functionalities such as sports management, counselling and well-being. It allows schools to manage parent and student relations and includes custom-built health and child safety guarding features. It also includes back-office operations such as revenue management, HR, payroll, finance and procurement.
Tmrw is not just a technology company, but an education transformation company that offers comprehensive educational services such as:
- Tmrw Academy – focused on professional development including teacher training
- Education Command Center – serving policy makers with real-time decision-making capabilities at a national level
- Tech-In-A-Box – Comprehensive technology backbone covering the school eco system end to end.
- Tmrw Advisory Services for educational institutions on curriculum design, digital transformation, school improvement and nation-wide educational strategies.
Spun out from GEMS Education, Tmrw has been incorporated as the independent technology entity of GEMS and so will draw on the experience of the largest private K-12 education provider in the world, where its solutions have proven themselves to be scalable and effective with real students in a real classroom environment. GEMS Education, since it was founded 62 years ago, has provided a quality and values driven education throughout the world.
During the pandemic, GEMS Education moved seamlessly online from the start of the crisis because for the last decade it has built, tested, and constantly improved an education platform with real teachers and real students in real classrooms. This culture of improvement, driven both by analytics and constant engagement with the experience of teachers and partners, will be at the heart of Tmrw.
Today, GEMS is the only private-sector education operator with an all-inclusive platform for teachers, pupils, and parents. That experience is the foundation of Tmrw, which seeks to create an impact on a billion learners through technology, backed by a team that has touched millions of lives over decades.
Mr. Sunny Varkey, Chairman and Founder of Tmrw and GEMS Education, said:
“Quality education is the great equaliser. It bridges the gap between the rich and the poor and gives us the greatest opportunity to improve the state of our world.
“We have built this platform to be accessible and affordable for Government funded schools throughout the world to help improve learning outcomes wherever we can. We seek to reach all students irrespective of their background or their ability to pay. Ultimately, our vision is to give every child their birth-right of a great education and provide hope for a better future.
“We can only achieve this mission if we learn lessons from the frontline of education. For far too long edtech has side-lined the voice of the teacher. Not this time, as teachers will be the beating heart of Tmrw. They will be our designers, our content creators and our toughest critics.”
Tmrw CEO and GEMS Education Group Chief Disruption Officer, Mr Krishnan Gopi, said:
“Education is transforming at pace, moving away from the conventional patterns of teaching and learning that have dominated the sector. There is an undeniable, growing awareness among educators and families that education must evolve to meet tomorrow’s reality.
“Designed by educators for educators, Tmrw will help students learn better, teachers teach better, parents become more engaged, and schools become more efficient”.
Our platform is secure, scalable, multi-lingual and highly configurable to meet different needs of education systems across the globe. It utilizes exponential technologies such as AI / ML, AR /VR, Blockchain and IOT to revolutionise the teaching and learning experience.
*For more information about how Tmrw can empower schools to deliver enhanced teaching and learning outcomes please email: info@tmrw.group
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005768/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
